QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 metagenomi-prioritizes-hemophilia-a-program-lays-off-25-workforce

Metagenomi reports curative-level FVIII activity for MGX-001 in primates and plans IND filing in 2026, extending cash runway in...

 ionis-reports-substantial-drop-in-acute-pancreatitis-events-with-cholesterol-lowering-drug

Ionis' olezarsen cut triglycerides by up to 72% and reduced acute pancreatitis events by 85% in Phase 3 studies of severe h...

 hc-wainwright--co-maintains-buy-on-ionis-pharmaceuticals-raises-price-target-to-110

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and raises the p...

 ionis-pharmaceuticals-study-results-of-olezarsen-for-severe-hypertriglyceridemia-show-up-to-72-placebo-adjusted-mean-reduction-in-fasting-triglyceride-levels-at-six-months-with-reductions-sustained-through-12-months

Groundbreaking pivotal study results of olezarsen for severe hypertriglyceridemia (sHTG) presented as a late breaker at AHA Sci...

 ionis-pharmaceuticals-releases-long-term-data-for-dawnzera-showing-durable-efficacy-and-safety

DAWNZERA showed durable efficacy, demonstrating 94% overall mean HAE attack rate reduction at one year in OASISplus open-label ...

 cathie-wood-goes-all-in-on-peter-thiels-crypto-play-bullish-with-back-to-back-million-dollar-buys

Cathie Wood-led Ark Invest purchased shares in Bullish, a crypto exchange backed by Peter Thiel, through three of its funds. Ot...

 piper-sandler-maintains-overweight-on-ionis-pharmaceuticals-raises-price-target-to-77

Piper Sandler analyst Allison Bratzel maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and raises the price t...

 td-cowen-maintains-buy-on-ionis-pharmaceuticals-raises-price-target-to-99

TD Cowen analyst Yaron Werber maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and raises the price target from $59 ...

 morgan-stanley-maintains-overweight-on-ionis-pharmaceuticals-raises-price-target-to-94

Morgan Stanley analyst Michael Ulz maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and raises the price targ...

 barclays-maintains-overweight-on-ionis-pharmaceuticals-raises-price-target-to-95

Barclays analyst Gena Wang maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and raises the price target from ...

 hc-wainwright--co-maintains-buy-on-ionis-pharmaceuticals-raises-price-target-to-100

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and raises the p...

 rbc-capital-maintains-outperform-on-ionis-pharmaceuticals-raises-price-target-to-82

RBC Capital analyst Luca Issi maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Outperform and raises the price target fr...

 raymond-james-reiterates-strong-buy-on-ionis-pharmaceuticals-raises-price-target-to-89

Raymond James analyst Gary Nachman reiterates Ionis Pharmaceuticals (NASDAQ:IONS) with a Strong Buy and raises the price tar...

 needham-maintains-buy-on-ionis-pharmaceuticals-raises-price-target-to-90

Needham analyst Joseph Stringer maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and raises the price target from $7...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION